Shares of HCA Healthcare, Inc. (NYSE: HCA) below -1.42% and ended at $105.22. The stock’s market capitalization arrived at $36.753B and total traded volume was 2,068,697 shares. The stock has a 52-week highest price of $108.85 and its 52-week lowest price was called at $71.18. During last trade, its maximum trading price was registered $106.66 and it’s the minimum trading price was noted $104.68.
HCA Healthcare, Inc. (HCA) recently reported financial and operating results for the first quarter ended March 31, 2018.
Key first quarter metrics (all percentage changes compare 1Q 2018 to 1Q 2017 unless noted):
- Revenues raised 7.5 percent to $11.423B
- Net income attributable to HCA Healthcare, Inc. totaled $1.144B, or $3.18 per diluted share
- Adjusted EBITDA totaled $2.118B
- Cash flows from operations totaled $1.300B
- Same facility equivalent admissions raised 1.8 percent, while same facility admissions raised 2.2 percent
- Same facility revenue per equivalent admission raised 3.9 percent
Revenues in the first quarter raised to $11.423B, contrast to $10.623B in the first quarter of 2017. Net income attributable to HCA Healthcare, Inc. totaled $1.144B, or $3.18 per diluted share, contrast to $659M, or $1.74 per diluted share, in the first quarter of 2017.
First quarter 2018 results include gains on sales of facilities of $405M, or $0.85 per diluted share, primarily reflecting the sale of our Oklahoma facilities. The Company recognized a tax benefit of $92M, or $0.26 per diluted share, in the first quarter of 2018 contrast to $67M, or $0.18 per diluted share, in the first quarter of 2017 related to employee equity award settlements.
Adjusted EBITDA totaled $2.118B contrast to $2.005B in the first quarter of 2017. Adjusted EBITDA is a non-GAAP financial measure. A table reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.
Same facility equivalent admissions and admissions raised 1.8 and 2.2 percent, respectively, in the first quarter of 2018, contrast to the previous year period. Same facility emergency room visits raised 3.5 percent in the first quarter of 2018, contrast to the previous year period. Inpatient surgeries raised 0.3 percent, while outpatient surgeries declined 0.5 percent in the first quarter of 2018 contrast to the same period of 2017, on a same facility basis. Same facility revenue per equivalent admission raised 3.9 percent in the first quarter of 2018 contrast to the first quarter of 2017.
During the first quarter of 2018, salaries and benefits, supplies and other operating expenses totaled $9.314B, or 81.6 percent of revenues, contrast to $8.628B, or 81.2 percent of revenues, in the first quarter of 2017.
Balance Sheet and Cash Flow
As of March 31, 2018, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $1.086B, total debt of $33.291B, and total assets of $37.299B. During the first quarter of 2018, capital expenditures totaled $694M, not including acquisitions. Cash flows provided by operating activities in the first quarter totaled $1.300B contrast to $1.280B in the previous year’s first quarter. As of March 31, 2018, HCA’s leverage ratio as measured by Total Debt/Adjusted EBITDA was 3.99x, contrast to 4.02x as of December 31, 2017.
The Company repurchased 4.370M shares of its ordinary stock at a cost of $423M during the first quarter of 2018. At March 31, 2018, the Company had $1.379B remaining under the existing $2.0B repurchase authorization. The Company had 350.987M shares outstanding as of March 31, 2018.
As of March 31, 2018, HCA operated 178 hospitals and about 1,800 sites of care, including surgery centers, freestanding ERs, urgent care centers and physician clinics, in 20 states and the United Kingdom.
Dividend
HCA recently reported that its Board of Directors reported a quarterly cash dividend of $0.35 per share on the Company’s ordinary stock. The dividend will be paid on June 29, 2018 to stockholders of record at the close of business on June 1, 2018.
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition and results of operations and contractual restrictions. Future dividends are predictable to be funded by cash balances and future cash flows from operations.
The company has the institutional ownership of 74.60% while the Beta factor was 0.48. The stock’s RSI amounts to 54.78. (HCA) EPS growth ratio for the past five years was 14.10% while Sales growth for the past five years was 5.70%. Return on equity (ROE) was noted as -40.60% while return on investment (ROI) was 17.80%.
